SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Illumina, Inc. and Certain Officers – ILMN

NEW YORK, Jan. 11, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ:ILMN) and certain of its officers.   The class action, filed in United States District Court, Southern District of California, and docketed under 17-cv-00053, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Illumina securities between July 26, 2016 and October 10, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Illumina securities during the Class Period, you have until February 14, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Illumina purportedly provides sequencing- and array-based solutions for genetic analysis.  The Company claims that its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (1) the Company was experiencing a large decline in high throughput sequencing instrument sales; (2) that the decline was negatively impacting the Company’s revenue; (3) that the Company lacked visibility into trends that could have a substantial impact on the Company’s financial results; (4) that, as such, the Company’s revenue guidance was unreliable and overstated; and (5) that, as a result of the foregoing, Defendants’ positive statements about Illumina’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On October 10, 2016, Illumina issued a press release entitled “Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016.”  Therein, the Company announced estimated third quarter revenue of approximately $607 million, which was lower than the Company’s third quarter revenue guidance of $625 million to $630 million.  The Company attributed the shortfall to “larger than anticipated year-over-year decline in high throughput sequencing instruments.”  The Company also announced that it expected fourth quarter revenue to be flat to slightly up sequentially.

On this news, Illumina’s stock price fell $45.86 per share, or 24.8%, to close at $138.99 per share on October 11, 2016, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby
Pomerantz LLP
[email protected]